IQVIA (NYSE:IQV) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of IQVIA (NYSE:IQVFree Report) in a report issued on Thursday, Marketbeat reports. The firm issued a buy rating and a $270.00 price target on the medical research company’s stock.

IQV has been the subject of several other research reports. BTIG Research began coverage on IQVIA in a research report on Tuesday, February 13th. They set a buy rating and a $285.00 target price for the company. Robert W. Baird decreased their price target on shares of IQVIA from $254.00 to $245.00 and set a neutral rating for the company in a research note on Friday, May 3rd. Truist Financial decreased their price target on shares of IQVIA from $297.00 to $292.00 and set a buy rating for the company in a research note on Friday, May 3rd. SVB Leerink initiated coverage on shares of IQVIA in a research note on Monday, February 26th. They set an outperform rating and a $290.00 price target for the company. Finally, Evercore ISI decreased their price target on shares of IQVIA from $275.00 to $250.00 and set an outperform rating for the company in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of Moderate Buy and an average price target of $258.40.

Check Out Our Latest Analysis on IQVIA

IQVIA Stock Up 0.7 %

Shares of NYSE:IQV opened at $220.49 on Thursday. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73. The business has a 50 day simple moving average of $231.66 and a two-hundred day simple moving average of $229.91. The firm has a market capitalization of $40.17 billion, a PE ratio of 30.12, a price-to-earnings-growth ratio of 1.98 and a beta of 1.53. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88.

IQVIA (NYSE:IQVGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. On average, equities analysts predict that IQVIA will post 10.11 EPS for the current year.

Hedge Funds Weigh In On IQVIA

Large investors have recently bought and sold shares of the business. AdvisorNet Financial Inc lifted its holdings in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. Rise Advisors LLC acquired a new stake in IQVIA in the first quarter worth about $31,000. BKM Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $32,000. Riverview Trust Co acquired a new position in shares of IQVIA during the first quarter valued at about $32,000. Finally, Activest Wealth Management purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $35,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.